The top 5 most-read articles about chronic kidney disease (CKD) focused on finerenone benefits, anticoagulants, dementia association, and more.
The top 5 most-read articles about chronic kidney disease (CKD) featured on AJMC.com this year included a discussion about the ability of sodium-glucose contransporter-2 (SGLT2) inhibitors to address CKD in patients with diabetes and included an article on the link between kidney function and dementia incidence, among other top stories.
Here are the 5 most viewed CKD articles of 2022.
5. Use of Anticoagulants Has Increased for Patients with Atrial Fibrillation, CKD
The use of direct oral anticoagulants increased in patients with atrial fibrillation and all stages of CKD, excluding severe and end-stage CKD, according to this article published in September that covered study findings. Use of warfarin decreased from 90.8% to 10.7% from 2013 to 2018 whereas the proportion of the study population that began treatment with direct oral anticoagulants increased from 9.2% to 89.3%.
4. Families Need Knowledge, Health Care Support When Caring for Patients With Kidney Failure, Review Finds
Psychological burden from uncertainty and anxiety linked to lack of knowledge on the diagnosis and prognosis of CKD was common in families caring for patients receiving comprehensive conservative care, according to an article written in March. The authors of the review wrote that incorporating family members in the care process through a paradigm shift in society and improved quality of health care would be vital in shifting the view of the family as only a resource for patient care.
3. Finerenone Reduces Heart Failure Risk in Patients With CKD, T2D
Use of the drug finerenone was demonstrated to reduce the odds of developing heart failure and could improve other heart failure–related outcomes in patients with CKD and type 2 diabetes (T2D), according to this article published in March that covered study findings. Screening for albuminuria and receiving early treatment could also reduce the burden of heart failure in patients with CKD and T2D.
2. SGLT2 Inhibitors, Combination Therapy Needed to Stem the Tide of CKD in Diabetes
A discussion with Katherine R. Tuttle, MD, FASN, FACP, FNKF, which was published in August as part of our coverage of the American Society for Preventive Cardiology meeting, focused on creating a more holistic approach to glucose control in a way that would protect the heart and the kidneys. Tuttle said that SGLT2 inhibitors have demonstrated benefits to the heart, kidneys, and all-cause mortality in patients with diabetes in cardiovascular outcome trials.
1. Poor Kidney Function Significantly Linked With Dementia Incidence
A 10-year follow-up of a cohort study found that poor and declining kidney function is associated with a higher risk of dementia in older adults, according to an article published in February that reported on the results. The study also found that the association could not be attributed to stroke and persisted after accounting for major cardiometabolic conditions. Previous studies had demonstrated a link between cognitive impairment and end-stage renal disease and CKD.
Long-Term Benefits Show the Value of Upfront Investments in Value-Based Care
October 17th 2024Miriam Godwin, CMMI, National Kidney Foundation, touches on the gaps in kidney care that public policy can address, as well as the importance of thinking about the long-term benefits of value-based care.
Read More
More Needs to Be Done to Reduce Racial Disparities in Home Dialysis
March 24th 2023On this episode of Managed Care Cast, we speak with Virginia Wang, PhD, and Matthew L. Maciejewski, PhD, who talk about their recent study on racial disparities in home dialysis, and what more needs to be done to increase uptake and reduce disparities in home dialysis for non-White patients.
Listen
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More